A randomized, placebo-controlled trial validates a side effect frequently observed by doctors and patients. A new study from ...

A trial exploring the use of a higher dose of Novo Nordisk's GLP-1 agonist semaglutide ... in weight in the REDEFINE 1 study over 68 weeks that fell short of Novo Nordisk's hope of a 25% loss.

Semaglutide — the active ingredient in the brand-name meds Ozempic, Wegovy, and Rybelsus — treats type 2 diabetes and obesity ...

WEIGHT loss jabs could raise the risk of a “potentially blinding condition” known as an “eye stroke”, researchers have warned ...

Researchers said the study backs up anecdotal evidence from patients and doctors that semaglutide can lead to a sudden loss of longing for alcoholic drinks ...

For years, conventional wisdom has been that weight loss is a matter of willpower. Those who are overweight or obese just need to try harder to eat less and exercise more. But while diet and ...

Federal regulators say shortages of Ozempic and Wegovy have been resolved, as supplies of popular diabetes and obesity ...

The new weight loss drug offers promising results for those who are overweight or obese. Learn about how Zepbound works, its ...

Research found that semaglutide, the active substance in Ozempic and the weight-loss drug Wegovy, could help curb alcohol ...

Compounding pharmacies producing cheaper semaglutide products have been given notice they will soon have to stop, as the drug ...

One participant lost 22% of her weight in nine months — substantially faster than the rate seen with approved GLP-1 drugs ...